interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Amlodipine Benzoate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Amlodipine Benzoate, and who makes it?

Amlodipine Benzoate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 3.9 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Amlodipine Benzoate1 dosage-form group in the Orange Book
0generic makers listed
  1. Amlodipine Benzoate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 3.9 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Katerzia. No generic is listed as marketed (1 generic product listed as discontinued).

20152020202520302035204001brand 2019data datePatent 10959991 listed to expire 6 October 2037Patent 10894039 listed to expire 6 October 2037Patent 11471409 listed to expire 6 October 2037Patent 12336984 listed to expire 6 October 2037Patent 11918685 listed to expire 6 October 2037Patent 11701326 listed to expire 6 October 2037Patent 11484498 listed to expire 6 October 2037Patent 12721843 listed to expire 6 October 2037Patent 10952998 listed to expire 6 October 2037Patent 12383498 listed to expire 6 October 2037Patent 11364230 listed to expire 6 October 2037Patent 12053461 listed to expire 6 October 2037Patent 10695329 listed to expire 16 October 2037Patent 10799453 listed to expire 11 April 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 6 October 2037Patent 10959991
  • 6 October 2037Patent 10894039
  • 6 October 2037Patent 11471409
  • 6 October 2037Patent 12336984
  • 6 October 2037Patent 11918685
  • 6 October 2037Patent 11701326 drug product
  • 6 October 2037Patent 11484498 drug product
  • 6 October 2037Patent 12721843 drug product

6 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.